Status:
ACTIVE_NOT_RECRUITING
An Observational Study to Learn More About Treatment Patterns and Factors Determining the Choice of Treatment in Canadian Men With Metastatic Hormone Sensitive Prostate Cancer in Routine Medical Care
Lead Sponsor:
Bayer
Conditions:
Metastatic Hormone-sensitive Prostate Cancer
Eligibility:
MALE
18+ years
Brief Summary
This is an observational study in which only data are collected from adult Canadian men with metastatic hormone sensitive prostate cancer (mHSPC) are studied. Participants will not receive any advice ...
Eligibility Criteria
Inclusion
- Men aged ≥ 18 years diagnosed with mHSPC verified by radiographic evidence of metastasis with Conventional Imaging (CI) or Prostate Specific Membrane Antigen-Positron Emission Tomography (PSMA-PET), and histologically confirmed carcinoma
- At least 6 months follow-up post-diagnosis period, unless the patient died earlier
Exclusion
- ADT use for \>6 months or any use of ARPi (ADT use in the neoadjuvant or adjuvant setting where the patient has been off treatment for 12 months or more is allowed)
- This criterion is to ensure that we are capturing mHSPC patients and not Metastatic Castration-Resistant Prostate Cancer (mCRPC) patients who have progressed from earlier stages
- Evidence of inclusion in clinical trials during the study period
Key Trial Info
Start Date :
February 28 2025
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 31 2026
Estimated Enrollment :
700 Patients enrolled
Trial Details
Trial ID
NCT06874114
Start Date
February 28 2025
End Date
December 31 2026
Last Update
September 2 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Pentavere
Toronto, Ontario, Canada, M6G 1A1